Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Challenges of in vitro drug release testing in case of advanced mucosal formulations (CROSBI ID 662987)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Jug, Mario Challenges of in vitro drug release testing in case of advanced mucosal formulations // PDDS 2018 Book of Abstracts / Torchilin, Vladimir P. ; Caira, Mino R. ; Hutcheon, Gillian (ur.). Rim: Magnus Group, 2018. str. 52-52

Podaci o odgovornosti

Jug, Mario

engleski

Challenges of in vitro drug release testing in case of advanced mucosal formulations

Mucosal route of drug delivery is recognised as suitable alternative to conventional drug administration routes (i.e. oral and parenteral), providing the possibility of more efficient local therapy with reduced systemic drug exposure as well as alternative application route for drugs that undergo extensive biotransformation in liver that leads to low and variable oral bioavailability. Nowadays, nanotechnology has been introduced to such delivery systems in order to improve their efficiency and safety. All this brings new challenges in evaluation of such formulations, prompting us to critically revise and upgrade the currently used methodology. In vitro release test is an important assay both in product development phase as well as in its quality control assurance. However, considering the diversity in formulations design, physicochemical and release characteristics of mucosal delivery systems, it is not possible to devise a single method which would be suitable for such purpose. This presentation is aimed to offer an extensive overview of currently available methodologies, both compendial and noncompendial, for in vitro drug release testing of mucosal delivery systems aimed for ocular, nasal, oromucosal, vaginal and rectal application. Critical parameters of such assays and instrumental setups will be discussed in details with a special focus on the evaluation of nanodelivery systems. In order to avoid unnecessary proliferation of equipment and method design, compendial apparatuses and methods should be used as a first approach in method development when applicable. Equipment set up, the selection of dissolution media type and volume, membrane characteristics, agitation speed, temperature, and assay analysis technique need to be carefully selected based on the properties of mucosal drug delivery system. The final goal of the method development is to obtain adequate simulation of conditions present in vivo at the application site. This would lead to development of novel biorelevant in vitro dissolution/release methods should that would enable better prediction of formulation performance in vivo and, preferably, the establishment of an in vitro/in vivo correlation.

in vitro drug releas ; mucosal delivery systems ; ocular delivery ; nasal delivery ; oromucosal delivery ; vaginal delivery ; rectal delivery

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

52-52.

2018.

objavljeno

Podaci o matičnoj publikaciji

PDDS 2018 Book of Abstracts

Torchilin, Vladimir P. ; Caira, Mino R. ; Hutcheon, Gillian

Rim: Magnus Group

Podaci o skupu

2nd Global Conference on Pharmaceutics and Drug Delivery systems

radionica

04.06.2018-06.06.2018

Rim, Italija

Povezanost rada

Farmacija